1. Home
  2. SAR vs CABA Comparison

SAR vs CABA Comparison

Compare SAR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$22.05

Market Cap

360.3M

Sector

Finance

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.33

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
CABA
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.3M
319.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SAR
CABA
Price
$22.05
$3.33
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$23.75
$14.50
AVG Volume (30 Days)
98.2K
4.3M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
14.34%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.39
N/A
P/E Ratio
$9.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.78
$1.26
52 Week High
$25.64
$4.23

Technical Indicators

Market Signals
Indicator
SAR
CABA
Relative Strength Index (RSI) 42.73 48.38
Support Level $21.40 $2.17
Resistance Level $23.74 $3.54
Average True Range (ATR) 0.43 0.34
MACD -0.12 -0.01
Stochastic Oscillator 6.51 39.93

Price Performance

Historical Comparison
SAR
CABA

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: